AT-III significantly and dose-dependently suppressed gastric ulcer formation via inhibiting matrix metalloproteinase (MMP)-2 and MMP-9 expression, decreasing the extracellular matrix (ECM) damage and preventing gastric ulcer formation [127]. This evidence concerns the gene SERPINC1 and gastric ulcer.